| 6 |
I would like to take this opportunity to welcome you to PLIVA, the leading pharmaceutical company in Central and Eastern Europe. Since its 1996 listing on the London and Zagreb Stock Exchanges, PLIVA has made notable advancements in internationalising its business and implementing a global and innovative strategy. PLIVA is a rather unique company with investments in both research and development. With over 400 patents in its possession, PLIVA has proven the high calibre of its R&D capabilities, most notably through the discovery of its blockbuster - azithromycin. This macrolide antibiotic, globally known as Zithromax (under license to Pfizer) or Sumamed (PLIVA’s brand), is the top selling antibiotic in its class. Building on its long history of R&D expertise and innovation, PLIVA has developed strong NCE and Generics programmes, an invaluable investment for PLIVA's sustained growth. Our business model and processes are the optimal combination of these R&D activities with international expansion through which PLIVA will continue to grow and enhance shareholder value. |
I would like to take this opportunity to welcome you to PLIVA, the leading pharmaceutical company in Central and Eastern Europe. Since its 1996 listing on the London and Zagreb Stock Exchanges, PLIVA has made notable advancements in internationalising its business and implementing a global and innovative strategy. PLIVA is a rather unique company with investments in both research and development. With over 400 patents in its possession, PLIVA has proven the high calibre of its R&D capabilities, most notably through the discovery of its blockbuster - azithromycin. This macrolide antibiotic, globally known as Zithromax (under license to Pfizer) or Sumamed (PLIVA's brand), is the top selling antibiotic in its class. Building on its long history of R&D expertise and innovation, PLIVA has developed strong NCE and Generics programmes, an invaluable investment for PLIVA's sustained growth. Our business model and processes are the optimal combination of these R&D activities with international expansion through which PLIVA will continue to grow and enhance shareholder value. |
| 8 |
<p align=left>I am very proud of PLIVA's accomplishments, but most of all, I take pride in our people, who made these advancements possible. The innovation and commitment of scientists and technicians in PLIVA's Research Institute has led to the discovery of azithromycin as well as the start of clinical trials for a number of new drugs and the development of over 40 new generic drugs. |
<p align=left>I am very proud of PLIVA's accomplishments, but most of all, I take pride in our people, who made these advancements possible. The innovation and commitment of scientists and technicians in PLIVA's Research Institute has led to the discovery of azithromycin as well as the start of clinical trials for a number of new drugs and the development of over 40 new generic drugs. |
Parent Directory
| 
Revision Log
| 
Patch